['ANTIRETROVIRAL AGENTS', 'PROTEASE INHIBITOR: ATAZANAVIR', '\xe2\x86\x93ATAZANAVIR CONCENTRATION \xe2\x86\x91 TENOFOVIR CONCENTRATION', 'COADMINISTRATION OF ATAZANAVIR WITH ATRIPLA IS NOT RECOMMENDED. COADMINISTRATION OF ATAZANAVIR WITH EITHER EFAVIRENZ OR TENOFOVIR DF DECREASES PLASMA CONCENTRATIONS OF ATAZANAVIR. THE COMBINED EFFECT OF EFAVIRENZ PLUS TENOFOVIR DF ON ATAZANAVIR PLASMA CONCENTRATIONS IS NOT KNOWN. ALSO, ATAZANAVIR HAS BEEN SHOWN TO INCREASE TENOFOVIR CONCENTRATIONS. THERE ARE INSUFFICIENT DATA TO SUPPORT DOSING RECOMMENDATIONS FOR ATAZANAVIR OR ATAZANAVIR/RITONAVIR IN COMBINATION WITH ATRIPLA.', 'PROTEASE INHIBITOR: FOSAMPRENAVIR CALCIUM', '\xe2\x86\x93 AMPRENAVIR CONCENTRATION', 'FOSAMPRENAVIR (UNBOOSTED): APPROPRIATE DOSES OF FOSAMPRENAVIR AND ATRIPLA WITH RESPECT TO SAFETY AND EFFICACY HAVE NOT BEEN ESTABLISHED. FOSAMPRENAVIR/RITONAVIR: AN ADDITIONAL 100 MG/DAY (300 MG TOTAL) OF RITONAVIR IS RECOMMENDED WHEN ATRIPLA IS ADMINISTERED WITH FOSAMPRENAVIR/RITONAVIR ONCE DAILY. NO CHANGE IN THE RITONAVIR DOSE IS REQUIRED WHEN ATRIPLA IS ADMINISTERED WITH FOSAMPRENAVIR PLUS RITONAVIR TWICE DAILY.', 'PROTEASE INHIBITOR: INDINAVIR', '\xe2\x86\x93 INDINAVIR CONCENTRATION', 'THE OPTIMAL DOSE OF INDINAVIR, WHEN GIVEN IN COMBINATION WITH EFAVIRENZ, IS NOT KNOWN. INCREASING THE INDINAVIR DOSE TO 1000 MG EVERY 8 HOURS DOES NOT COMPENSATE FOR THE INCREASED INDINAVIR METABOLISM DUE TO EFAVIRENZ.', 'PROTEASE INHIBITOR: LOPINAVIR/RITONAVIR', '\xe2\x86\x93 LOPINAVIR CONCENTRATION \xe2\x86\x91 TENOFOVIR CONCENTRATION', 'A DOSE INCREASE OF LOPINAVIR/RITONAVIR TO 600/150 MG (3 TABLETS) TWICE DAILY MAY BE CONSIDERED WHEN USED IN COMBINATION WITH EFAVIRENZ IN TREATMENT-EXPERIENCED PATIENTS WHERE DECREASED SUSCEPTIBILITY TO LOPINAVIR IS CLINICALLY SUSPECTED (BY TREATMENT HISTORY OR LABORATORY EVIDENCE). PATIENTS SHOULD BE MONITORED FOR TENOFOVIR-ASSOCIATED ADVERSE REACTIONS. ATRIPLA SHOULD BE DISCONTINUED IN PATIENTS WHO DEVELOP TENOFOVIR-ASSOCIATED ADVERSE REACTIONS .', 'PROTEASE INHIBITOR: RITONAVIR', '\xe2\x86\x91 RITONAVIR CONCENTRATION \xe2\x86\x91 EFAVIRENZ CONCENTRATION', 'WHEN RITONAVIR 500 MG EVERY 12 HOURS WAS COADMINISTERED WITH EFAVIRENZ 600 MG ONCE DAILY, THE COMBINATION WAS ASSOCIATED WITH A HIGHER FREQUENCY OF ADVERSE CLINICAL EXPERIENCES (E.G., DIZZINESS, NAUSEA, PARESTHESIA) AND LABORATORY ABNORMALITIES (ELEVATED LIVER ENZYMES). MONITORING OF LIVER ENZYMES IS RECOMMENDED WHEN ATRIPLA IS USED IN COMBINATION WITH RITONAVIR.', 'PROTEASE INHIBITOR: SAQUINAVIR', '\xe2\x86\x93 SAQUINAVIR CONCENTRATION', 'SHOULD NOT BE USED AS SOLE PROTEASE INHIBITOR IN COMBINATION WITH ATRIPLA.', 'CCR5 CO-RECEPTOR ANTAGONIST: MARAVIROC', '\xe2\x86\x93 MARAVIROC CONCENTRATION', 'EFAVIRENZ DECREASES PLASMA CONCENTRATIONS OF MARAVIROC. REFER TO THE FULL PRESCRIBING INFORMATION FOR MARAVIROC FOR GUIDANCE ON COADMINISTRATION WITH ATRIPLA.', 'NRTI: DIDANOSINE', '\xe2\x86\x91 DIDANOSINE CONCENTRATION', 'HIGHER DIDANOSINE CONCENTRATIONS COULD POTENTIATE DIDANOSINE-ASSOCIATED ADVERSE REACTIONS, INCLUDING PANCREATITIS AND NEUROPATHY. IN PATIENTS WEIGHING >60 KG, THE DIDANOSINE DOSE SHOULD BE REDUCED TO 250 MG IF COADMINISTERED WITH ATRIPLA . DATA ARE NOT AVAILABLE TO RECOMMEND A DOSE ADJUSTMENT OF DIDANOSINE FOR PATIENTS WEIGHING <60 KG. COADMINISTRATION OF ATRIPLA AND DIDANOSINE SHOULD BE UNDERTAKEN WITH CAUTION AND PATIENTS RECEIVING THIS COMBINATION SHOULD BE MONITORED CLOSELY FOR DIDANOSINE-ASSOCIATED ADVERSE REACTIONS. FOR ADDITIONAL INFORMATION, PLEASE CONSULT THE VIDEX / VIDEX EC (DIDANOSINE) PRESCRIBING INFORMATION.', 'OTHER AGENTS', 'ANTICOAGULANT: WARFARIN', '\xe2\x86\x91 OR \xe2\x86\x93 WARFARIN CONCENTRATION', 'PLASMA CONCENTRATIONS AND EFFECTS POTENTIALLY INCREASED OR DECREASED BY EFAVIRENZ.', 'ANTICONVULSANTS: CARBAMAZEPINE', '\xe2\x86\x93 CARBAMAZEPINE CONCENTRATION \xe2\x86\x93 EFAVIRENZ CONCENTRATION', 'THERE ARE INSUFFICIENT DATA TO MAKE A DOSE RECOMMENDATION FOR ATRIPLA. ALTERNATIVE ANTICONVULSANT TREATMENT SHOULD BE USED.', 'PHENYTOIN PHENOBARBITAL', '\xe2\x86\x93 ANTICONVULSANT CONCENTRATION \xe2\x86\x93 EFAVIRENZ CONCENTRATION', 'POTENTIAL FOR REDUCTION IN ANTICONVULSANT AND/OR EFAVIRENZ PLASMA LEVELS; PERIODIC MONITORING OF ANTICONVULSANT PLASMA LEVELS SHOULD BE CONDUCTED.', 'ANTIDEPRESSANTS: BUPROPION', '\xe2\x86\x93 BUPROPRION CONCENTRATION', 'THE EFFECT OF EFAVIRENZ ON BUPROPION EXPOSURE IS THOUGHT TO BE DUE TO THE INDUCTION OF BUPROPION METABOLISM. INCREASES IN BUPROPION DOSAGE SHOULD BE GUIDED BY CLINICAL RESPONSE, BUT THE MAXIMUM RECOMMENDED DOSE OF BUPROPION SHOULD NOT BE EXCEEDED.', 'SERTRALINE', '\xe2\x86\x93 SERTRALINE CONCENTRATION', 'INCREASES IN SERTRALINE DOSE SHOULD BE GUIDED BY CLINICAL RESPONSE.', 'ANTIFUNGALS: ITRACONAZOLE', '\xe2\x86\x93 ITRACONAZOLE CONCENTRATION \xe2\x86\x93 HYDROXY-ITRACONAZOLE CONCENTRATION', 'SINCE NO DOSE RECOMMENDATION FOR ITRACONAZOLE CAN BE MADE, ALTERNATIVE ANTIFUNGAL TREATMENT SHOULD BE CONSIDERED.', 'KETOCONAZOLE', '\xe2\x86\x93 KETOCONAZOLE CONCENTRATION', 'DRUG INTERACTION TRIALS WITH ATRIPLA AND KETOCONAZOLE HAVE NOT BEEN CONDUCTED. EFAVIRENZ HAS THE POTENTIAL TO DECREASE PLASMA CONCENTRATIONS OF KETOCONAZOLE.', 'POSACONAZOLE', '\xe2\x86\x93 POSACONAZOLE CONCENTRATION', 'AVOID CONCOMITANT USE UNLESS THE BENEFIT OUTWEIGHS THE RISKS.', 'ANTI-INFECTIVE: CLARITHROMYCIN', '\xe2\x86\x93 CLARITHROMYCIN CONCENTRATION \xe2\x86\x91 14-OH METABOLITE CONCENTRATION', 'CLINICAL SIGNIFICANCE UNKNOWN. IN UNINFECTED VOLUNTEERS, 46% DEVELOPED RASH WHILE RECEIVING EFAVIRENZ AND CLARITHROMYCIN. NO DOSE ADJUSTMENT OF ATRIPLA IS RECOMMENDED WHEN GIVEN WITH CLARITHROMYCIN. ALTERNATIVES TO CLARITHROMYCIN, SUCH AS AZITHROMYCIN, SHOULD BE CONSIDERED. OTHER MACROLIDE ANTIBIOTICS, SUCH AS ERYTHROMYCIN, HAVE NOT BEEN STUDIED IN COMBINATION WITH ATRIPLA.', 'ANTIMYCOBACTERIAL: RIFABUTIN', '\xe2\x86\x93 RIFABUTIN CONCENTRATION', 'INCREASE DAILY DOSE OF RIFABUTIN BY 50%. CONSIDER DOUBLING THE RIFABUTIN DOSE IN REGIMENS WHERE RIFABUTIN IS GIVEN 2 OR 3 TIMES A WEEK.', 'ANTIMYCOBACTERIAL: RIFAMPIN', '\xe2\x86\x93 EFAVIRENZ CONCENTRATION', 'IF ATRIPLA IS COADMINISTERED WITH RIFAMPIN TO PATIENTS WEIGHING 50 KG OR MORE, AN ADDITIONAL 200 MG/DAY OF EFAVIRENZ IS RECOMMENDED.', 'CALCIUM CHANNEL BLOCKERS: DILTIAZEM', '\xe2\x86\x93 DILTIAZEM CONCENTRATION \xe2\x86\x93 DESACETYL DILTIAZEM CONCENTRATION \xe2\x86\x93 N-MONODES-METHYL DILTIAZEM CONCENTRATION', 'DILTIAZEM DOSE ADJUSTMENTS SHOULD BE GUIDED BY CLINICAL RESPONSE (REFER TO THE FULL PRESCRIBING INFORMATION FOR DILTIAZEM). NO DOSE ADJUSTMENT OF ATRIPLA IS NECESSARY WHEN ADMINISTERED WITH DILTIAZEM.', 'OTHERS (E.G., FELODIPINE, NICARDIPINE, NIFEDIPINE, VERAPAMIL)', '\xe2\x86\x93 CALCIUM CHANNEL BLOCKER', 'NO DATA ARE AVAILABLE ON THE POTENTIAL INTERACTIONS OF EFAVIRENZ WITH OTHER CALCIUM CHANNEL BLOCKERS THAT ARE SUBSTRATES OF CYP3A. THE POTENTIAL EXISTS FOR REDUCTION IN PLASMA CONCENTRATIONS OF THE CALCIUM CHANNEL BLOCKER. DOSE ADJUSTMENTS SHOULD BE GUIDED BY CLINICAL RESPONSE (REFER TO THE FULL PRESCRIBING INFORMATION FOR THE CALCIUM CHANNEL BLOCKER).', 'HMG-COA REDUCTASE INHIBITORS: ATORVASTATIN PRAVASTATIN SIMVASTATIN', '\xe2\x86\x93 ATORVASTATIN CONCENTRATION \xe2\x86\x93\tPRAVASTATIN CONCENTRATION \xe2\x86\x93 SIMVASTATIN CONCENTRATION', 'PLASMA CONCENTRATIONS OF ATORVASTATIN, PRAVASTATIN, AND SIMVASTATIN DECREASED WITH EFAVIRENZ. CONSULT THE FULL PRESCRIBING INFORMATION FOR THE HMG-COA REDUCTASE INHIBITOR FOR GUIDANCE ON INDIVIDUALIZING THE DOSE.', 'HORMONAL CONTRACEPTIVES:', '', '', 'ORAL: ETHINYL ESTRADIOL/NORGESTIMATE', '\xe2\x86\x93 ACTIVE METABOLITES OF NORGESTIMATE', 'A RELIABLE METHOD OF BARRIER CONTRACEPTION MUST BE USED IN ADDITION TO HORMONAL CONTRACEPTIVES. EFAVIRENZ HAD NO EFFECT ON ETHINYL ESTRADIOL CONCENTRATIONS, BUT PROGESTIN LEVELS (NORELGESTROMIN AND LEVONORGESTREL) WERE MARKEDLY DECREASED. NO EFFECT OF ETHINYL ESTRADIOL/NORGESTIMATE ON EFAVIRENZ PLASMA CONCENTRATIONS WAS OBSERVED.', 'IMPLANT: ETONOGESTREL', '\xe2\x86\x93 ETONOGESTREL', 'A RELIABLE METHOD OF BARRIER CONTRACEPTION MUST BE USED IN ADDITION TO HORMONAL CONTRACEPTIVES. THE INTERACTION BETWEEN ETONOGESTREL AND EFAVIRENZ HAS NOT BEEN STUDIED. DECREASED EXPOSURE OF ETONOGESTREL MAY BE EXPECTED. THERE HAVE BEEN POSTMARKETING REPORTS OF CONTRACEPTIVE FAILURE WITH ETONOGESTREL IN EFAVIRENZ-EXPOSED PATIENTS.', 'IMMUNOSUPPRESSANTS: CYCLOSPORINE, TACROLIMUS, SIROLIMUS, AND OTHERS METABOLIZED BY CYP3A', '\xe2\x86\x93 IMMUNO-SUPPRESSANT', 'DECREASED EXPOSURE OF THE IMMUNOSUPPRESSANT MAY BE EXPECTED DUE TO CYP3A INDUCTION BY EFAVIRENZ. THESE IMMUNOSUPPRESSANTS ARE NOT ANTICIPATED TO AFFECT EXPOSURE OF EFAVIRENZ. DOSE ADJUSTMENTS OF THE IMMUNOSUPPRESSANT MAY BE REQUIRED. CLOSE MONITORING OF IMMUNOSUPPRESSANT CONCENTRATIONS FOR AT LEAST 2 WEEKS (UNTIL STABLE CONCENTRATIONS ARE REACHED) IS RECOMMENDED WHEN STARTING OR STOPPING TREATMENT WITH ATRIPLA.', 'NARCOTIC ANALGESIC: METHADONE', '\xe2\x86\x93 METHADONE CONCENTRATION', 'COADMINISTRATION OF EFAVIRENZ IN HIV-1 INFECTED INDIVIDUALS WITH A HISTORY OF INJECTION DRUG USE RESULTED IN DECREASED PLASMA LEVELS OF METHADONE AND SIGNS OF OPIATE WITHDRAWAL. METHADONE DOSE WAS INCREASED BY A MEAN OF 22% TO ALLEVIATE WITHDRAWAL SYMPTOMS. PATIENTS SHOULD BE MONITORED FOR SIGNS OF WITHDRAWAL AND THEIR METHADONE DOSE INCREASED AS REQUIRED TO ALLEVIATE WITHDRAWAL SYMPTOMS.']